1. 48P Phase II trial on vaccination with autologous dendritic cells loaded with autologous tumour homogenate in resected glioblastoma (COMBI-GVAX): Clinical results of the first step. (December 2022) Authors: Ridolfi, L.; Gurrieri, L.; Riva, M.N.; Bulgarelli, J.; Fausti, V.; F. de Rosa, ; Guidoboni, M.; Foca, F.; Tazzari, M.; Petrini, M.; Granato, A.M.; Pancisi, E.; Dall'Agata, M.; Amadori, E.; Gamboni, A.; Pasini, G.; Cortesi, P.; Mercatali, L.; Bongiovanni, A.; Tosatto, L. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 49P Exploiting multi-omic integrated data from DC-vaccinated melanoma patients for the generation of an advanced adoptive T cell therapy. (December 2022) Authors: Bulgarelli, J.; Tazzari, M.; Carloni, S.; Pignatta, S.; Bochicchio, M.T.; Bocchini, M.; Angeli, D.; Tebaldi, M.; Granato, A.M.; Piccinini, C.; Pancisi, E.; F. de Rosa, ; Ancarani, V.; Limarzi, F.; Petrini, M.; Ridolfi, L. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗